secwatch.observer — SEC 8-K summary
======================================

Issuer:     Omega Therapeutics, Inc. (—)
CIK:        0001850838
Form:       8-K
Filed at:   2024-04-16T23:59:59+00:00
Accession:  0000950170-24-044795
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Omega Therapeutics CFO Joshua Reed to depart May 31; Barbara Chan named successor
--------------------------------------------------------------------------------

- Joshua Reed's employment terminated effective May 31, 2024; severance and extended option exercisability.
- Barbara Chan, SVP Finance, appointed principal financial officer and principal accounting officer effective May 31.
- Chan also becomes Treasurer; has been at Omega since May 2020.
- Prior role: VP Finance and CAO at Aegerion Pharmaceuticals (2016-2019).
- Chan holds B.S. and M.S. in Accounting and Taxation from Bentley University.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850838/000095017024044795/0000950170-24-044795-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850838/000095017024044795/omga-20240410.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-044795

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer